» Articles » PMID: 37834295

The Effect of Gene Editing by CRISPR-Cas9 of MiR-21 and the Indirect Target MMP9 in Metastatic Prostate Cancer

Abstract

Prostate cancer (PCa) has a high prevalence and represents an important health problem, with an increased risk of metastasis. With the advance of CRISPR-Cas9 genome editing, new possibilities have been created for investigating PCa. The technique is effective in knockout oncogenes, reducing tumor resistance. MMP9 and miR-21 target genes are associated with PCa progression; therefore, we evaluated the MMP-9 and miR-21 targets in PCa using the CRISPR-Cas9 system. Single guide RNAs (sgRNAs) of MMP9 and miR-21 sequences were inserted into a PX-330 plasmid, and transfected in DU145 and PC-3 PCa cell lines. MMP9 and RECK expression was assessed by qPCR, WB, and IF. The miR-21 targets, integrins, BAX and mTOR, were evaluated by qPCR. Flow cytometry was performed with Annexin5, 7-AAD and Ki67 markers. Invasion assays were performed with Matrigel. The miR-21 CRISPR-Cas9-edited cells upregulated RECK, MARCKS, BTG2, and PDCD4. CDH1, ITGB3 and ITGB1 were increased in MMP9 and miR-21 CRISPR-Cas9-edited cells. Increased BAX and decreased mTOR were observed in MMP9 and miR-21 CRISPR-Cas9-edited cells. Reduced cell proliferation, increased apoptosis and low invasion in MMP9 and miR-21 edited cells was observed, compared to Scramble. CRISPR-Cas9-edited cells of miR-21 and MMP9 attenuate cell proliferation, invasion and stimulate apoptosis, impeding PCa evolution.

Citing Articles

Somatostatin receptor-targeted polymeric nanoplatform for efficient CRISPR/Cas9 gene editing to enhance synergistic hepatocellular carcinoma therapy.

Zhang S, Li M, Zeng J, Zhou S, Yue F, Chen Z J Nanobiotechnology. 2025; 23(1):127.

PMID: 39979929 PMC: 11844079. DOI: 10.1186/s12951-025-03214-3.


CRISPR/Cas9 Technology Providing the Therapeutic Landscape of Metastatic Prostate Cancer.

Park J, Kim J Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770431 PMC: 11676443. DOI: 10.3390/ph17121589.


MiR-21 Regulates Growth and Migration of Cervical Cancer Cells by RECK Signaling Pathway.

Aguilar-Martinez S, Campos-Viguri G, Medina-Garcia S, Garcia-Flores R, Deas J, Gomez-Ceron C Int J Mol Sci. 2024; 25(7).

PMID: 38612895 PMC: 11012906. DOI: 10.3390/ijms25074086.

References
1.
Wei C, Wang F, Liu W, Zhao W, Yang Y, Li K . CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells. Mol Med Rep. 2017; 17(2):2901-2906. PMC: 5783506. DOI: 10.3892/mmr.2017.8257. View

2.
Zhao W, Ning L, Wang L, Ouyang T, Qi L, Yang R . miR-21 inhibition reverses doxorubicin-resistance and inhibits PC3 human prostate cancer cells proliferation. Andrologia. 2021; 53(5):e14016. DOI: 10.1111/and.14016. View

3.
Yuan J, Li W, Zhu J, Deng S, Tao X . Low expression of RECK in oral squamous cell carcinoma patients induces a shorter survival rate through an imbalance of RECK/MMPs. Int J Clin Exp Pathol. 2020; 13(3):501-508. PMC: 7136997. View

4.
Fei T, Chen Y, Xiao T, Li W, Cato L, Zhang P . Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proc Natl Acad Sci U S A. 2017; 114(26):E5207-E5215. PMC: 5495225. DOI: 10.1073/pnas.1617467114. View

5.
Kim K, Kim H, Lee C, Kim S, Cheon G, Kang K . Therapeutic efficacy of modified anti-miR21 in metastatic prostate cancer. Biochem Biophys Res Commun. 2020; 529(3):707-713. DOI: 10.1016/j.bbrc.2020.05.215. View